12:00 AM
 | 
Nov 23, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Imetelstat: Phase I data

Interim data from an ongoing Phase I trial in 25 patients showed that dose escalation to 11.7 mg/kg imetelstat led to hematologic toxicities and was considered to exceed the...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >